Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents

D. J. Chaplin, George Pettit, C. S. Parkins, S. A. Hill

Research output: Contribution to journalArticlepeer-review

174 Scopus citations


We have assessed the vascular effects of vinblastine and four other tubulin binding agents (dolastatin 10, dolastatin 15, combretastatin A1 and combretastatin A4), which are awaiting clinical evaluation. All five agents induce a reduction in tumour blood Bow as measured by uptake of RbCl 24 h post drug administration. The degree of reduction ranged from 50% with combretastatin A1 to 90% with dolastatin 10. These reductions were similar to that seen with flavone acetic acid (FAA) and indicate that antivascular effects are a common feature of tubulin binding agents. We subsequently evaluated whether the blood flow reductions, induced by FAA and vinblastine, could be used to enhance the activity of the bioreductive drug tirapazamine. Since the kinetics and extent of blood flow reductions induced by the agents is comparable, similar therapeutic response was expected. Potentiation was only evident with FAA, indicating that this effect is not directly related to killing of hypoxic tumour cells induced as a consequence of blood flow reduction.

Original languageEnglish (US)
Pages (from-to)S86-S88
JournalBritish Journal of Cancer
Issue numberSUPPL. XXVII
StatePublished - 1996


  • Bloodflow
  • Combretastatin
  • Dolastatin
  • FAA
  • Tirapazamine
  • Vinblastine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents'. Together they form a unique fingerprint.

Cite this